Tandem Diabetes Care INC Form 4 insider transactions

Jean-Claude Kyrillos, EVP & Chief Operating Officer of Tandem Diabetes Care Inc, reported multiple transactions in common stock on July 15, 2026.

Elizabeth Anne Gasser, EVP, Chief Strategy Officer at Tandem Diabetes Care Inc., transferred 7,160 shares of common stock to a family trust on June 2, 2026.

Tandem Diabetes Care Inc. reports that President & CEO John F. Sheridan was granted 191,103 restricted stock units under the company's 2023 Long-Term Incentive Plan.

Elizabeth Gasser, EVP, Chief Strategy Officer at Tandem Diabetes Care, was granted 29,136 Restricted Stock Units on May 29, 2026.

Leigh Vosseller, EVP & CFO of Tandem Diabetes Care, received a grant of 62,657 Restricted Stock Units (RSUs) on May 29, 2026.

Jean-Claude Kyrillos, EVP & COO of Tandem Diabetes Care, received a grant of 29,136 Restricted Stock Units (RSUs) on May 29, 2026.

Susan Morrison, EVP & Chief Admin. Officer of Tandem Diabetes Care, received 29,136 Restricted Stock Units on May 29, 2026.

Tandem Diabetes Care Inc. executive Rick Carpenter reported a transaction involving restricted stock units on May 29, 2026.

Shannon Marie Hansen of Tandem Diabetes Care Inc. received a grant of 29,136 Restricted Stock Units (RSUs) on May 29, 2026, with vesting scheduled over the next several years.

Dick Allen, Chair Emeritus of Tandem Diabetes Care, acquired 8,759 shares through RSU vesting and received a new grant of 10,220 units.

Director Peyton R. Howell acquired 10,220 restricted stock units and converted 8,759 units into common stock.

Director Joao Paulo Falcao Malagueira acquired 8,759 shares via RSU vesting and received a new grant of 10,220 RSUs.

Director Sandra Beaver was granted 5,110 restricted stock units as part of the company's 2023 Long-Term Incentive Plan.

Director Rajwant Sodhi acquired 8,759 shares via RSU vesting and was granted 10,220 new RSUs.

Director Kathleen McGroddy-Goetz acquired 8,759 shares of Tandem Diabetes Care common stock through the vesting of restricted stock units.

Tandem Diabetes Care Director Rebecca B. Robertson reported the vesting of 8,759 restricted stock units into common stock and the grant of 10,220 new restricted stock units.

Christopher J. Twomey, a director at Tandem Diabetes Care Inc., reported the vesting of 8,759 restricted stock units and the grant of 10,220 new units.

Director Myoungil Cha acquired 8,759 shares of Tandem Diabetes Care common stock through the vesting of restricted stock units.

Rick Carpenter, EVP & Chief Technology Officer at Tandem Diabetes Care Inc., reported transactions involving common stock, including acquisitions through an employee stock purchase plan and the withholding of shares for tax purposes.

Elizabeth Gasser, EVP, Chief Strategy Officer at Tandem Diabetes Care Inc., reported significant stock transactions including acquisitions and disposals of common stock and restricted stock units.

Shannon Marie Hansen, EVP & Chief Legal Officer of Tandem Diabetes Care Inc., reported transactions involving common stock and restricted stock units.

Jean-Claude Kyrillos, EVP & COO of Tandem Diabetes Care, reported stock transactions including RSU vesting and ESPP purchases.

Susan Morrison, EVP & Chief Admin. Officer of Tandem Diabetes Care Inc., reported transactions involving common stock and restricted stock units.

John F. Sheridan, President & CEO of Tandem Diabetes Care Inc., reported transactions including the acquisition of common stock through an employee stock purchase plan and the vesting of restricted stock units.

Leigh Vosseller, EVP & CFO of Tandem Diabetes Care Inc., reported transactions involving common stock, including RSU vesting and ESPP purchases.

Mark David Novara, EVP & Chief Commercial Officer of Tandem Diabetes Care Inc., reported transactions involving common stock and restricted stock units.

Jean-Claude Kyrillos, EVP and COO of Tandem Diabetes Care, reported the vesting of 3,636 restricted stock units and the withholding of 1,926 shares for tax obligations.

Mark Novara, EVP & Chief Commercial Officer of Tandem Diabetes Care, reported the vesting of restricted stock units and subsequent sale of shares, including for tax obligations.

Tandem Diabetes Care Inc.'s Chief Technology Officer, Rick Carpenter, reported the vesting of restricted stock units and subsequent tax-related share withholdings.

Tandem Diabetes Care's EVP, Chief Strategy Officer, Elizabeth Gasser, reported scheduled vesting of Restricted Stock Units and associated tax withholdings.